|
||
| |||||||
|
Introduction: Although it is clear that innovative therapies hold great potential, the precise role for each agent, the most effective route to the market and the sales potential for these novel pharmacotherapies is unclear. Datamonitor’s research into the cancer innovatives market forecasts the future role for these agents and their influence on shaping cancer therapy over the next ten years and beyond. Scope: * Opinion Leader interviews, discussing the likely evolution of the innovatives market, and high-profile innovative agents * Profiles and potential of key innovative agents in late-stage development * Market and agent forecasts to 2011 * Case scenarios illustrating the opportunities and threats faced by developers of innovative therapies along the path to commercialization Report Highlights: Immunostimulators, despite being early entrants to the cancer market, will be challenged by other innovative classes. However, individual agents within this class could drive market growth significantly within niche indications. Angiogenesis inhibitors, after some disappointing early results, still have potential as effective cytostatic agents. Developers of these agents must show synergy with cytotoxics to achieve significant market penetration, leading to a potential future role as long-term chronic therapy. Tumor-targeted agents have enormous potential for improving the management of late-stage disease. Successful agents will combine strong clinical data and a synergy to current cytotoxic regimens, to target niche markets with high levels of unmet need. Reasons to Purchase: * Identify which innovative agents and biological targets for new therapies are rated highly by opinion leaders, and which are not * Determine the price level of your product by assessing its positioning relative to marketed products, and other pipeline agents Predict the future potential of key innovative agents by analyzing the sales forecast for these drugs to 2011 Publisher: Datamonitor Oncology Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a257 |
|
|
